Kerstine Carter

Kerstine Carter

Auto-generated profile, based on publicly available information

Kerstine Carter

Global Biostatistics & Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2023 in Statistics in Biopharmaceutical Research
Verified
Journal Article
Open access
DUDiane Uschner
Diane Uschner
OSOleksandr Sverdlov
Oleksandr Sverdlov
KCKerstine Carter
Kerstine Carter
JCJonathan Chipman
Jonathan Chipman
OKOlga Kuznetsova
Olga Kuznetsova
WRWilliam F. Rosenberger
William F. Rosenberger

15 August 2023 in Statistics in Biopharmaceutical Research
Verified
Journal Article
Closed access
KCKerstine Carter
Kerstine Carter
ASAnnika L. Scheffold
Annika L. Scheffold
JRJone Renteria
Jone Renteria
VBVance W. Berger
Vance W. Berger
YLYuqun Abigail Luo
Yuqun Abigail Luo
OSOleksandr Sverdlov
Oleksandr Sverdlov

28 February 2024 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
OSOleksandr Sverdlov
Oleksandr Sverdlov
YRYevgen Ryeznik
Yevgen Ryeznik
VAVladimir Anisimov
Vladimir Anisimov
OKOlga M. Kuznetsova
Olga M. Kuznetsova
RKRuth Knight
Ruth Knight
WZWenle Zhao
Wenle Zhao
Background: The design of a multi-center randomized controlled trial (RCT) involves multiple considerations, such as the choice of the sample size, the number of centers and their geographic location, the strategy for recruitment of study participants, amongst others. There are plenty of methods to sequentially randomize patients in a multi-center RCT, with or without considering stratification factors. The goal of this paper is to perform a systematic assessment of such randomization methods for a multi-center 1:1 RCT assuming a competitive policy for the patient recruitment process. Methods: We considered a Poisson-gamma model for the patient recruitment process with a uniform distribution of center activation times. We investigated 16 randomization methods (4 unstratified, 4 region-stratified, 4 center-stratified, 3 dynamic balancing randomization (DBR), and a complete randomization design) to sequentially randomize $$n=500$$ n = 500 patients. Statistical properties of the recruitment process and the randomization procedures were assessed using Monte Carlo simulations. The operating characteristics included time to complete recruitment, number of centers that recruited a given number of patients, several measures of treatment imbalance and estimation efficiency under a linear model for the response, the expected proportions of correct guesses under two different guessing strategies, and the expected proportion of deterministic assignments in the allocation sequence. Results: Maximum tolerated imbalance (MTI) randomization methods such as big stick design, Ehrenfest urn design, and block urn design result in a better balance–randomness tradeoff than the conventional permuted block design (PBD) with or without stratification. Unstratified randomization, region-stratified randomization, and center-stratified randomization provide control of imbalance at a chosen level (trial, region, or center) but may fail to achieve balance at the other two levels. By contrast, DBR does a very good job controlling imbalance at all 3 levels while maintaining the randomized nature of treatment allocation. Adding more centers into the study helps accelerate the recruitment process but at the expense of increasing the number of centers that recruit very few (or no) patients—which may increase center-level imbalances for center-stratified and DBR procedures. Increasing the block size or the MTI threshold(s) may help obtain designs with improved randomness–balance tradeoff. Conclusions: The choice of a randomization method is an important component of planning a multi-center RCT. Dynamic balancing randomization with carefully chosen MTI thresholds could be a very good strategy for trials with the competitive policy for patient recruitment.


24 July 2025 in Statistical Methods in Medical Research
Verified
Journal Article
Closed access
OSOleksandr Sverdlov
Oleksandr Sverdlov
JRJone Renteria
Jone Renteria
KCKerstine Carter
Kerstine Carter
ASAnnika L Scheffold
Annika L Scheffold
JKJohannes Krisam
Johannes Krisam
JSJan Seidel
Jan Seidel
Background: There is emerging evidence of the increasing uptake of response-adaptive randomization (RAR) in clinical trials. However, a systematic review of RAR trials, their context of use, characteristics, and stakeholder acceptance has been lacking. Methods: We performed a systematic review of clinical trials that utilized elements of RAR, identified via the Cortellis Regulatory Intelligence database following a pre-specified selection process. We report a summary of relevant characteristics of the identified trials. Results: Out of 170 records, 39 RAR trials were identified (22 completed, 17 ongoing as of October 2024). The majority were Phase 2-focused studies (phases 1/2, 2, 2b, and 2/3), academically sponsored, and concentrated in oncology, neurology, and infectious diseases. Small molecules and biologics were the most common investigational products. Among the 22 completed trials, seven reported positive outcomes. Notably, two of these trials provided pivotal data that informed the further development and subsequent regulatory approval of the investigational compounds. Conclusion: Over the past two decades, RAR has been increasingly utilized in complex adaptive trials across diverse therapeutic areas and clinical research phases. This systematic review provides a critical “baseline” for tracing the dynamics of RAR applications and should help the clinical research community recognize RAR as a valuable methodology for optimizing future trial designs.